BiotechTube

Micafungin + Systemic antifungal therapy

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Invasive Aspergillosis

Conditions

Invasive Aspergillosis

Trial Timeline

Jun 1, 2006 → Sep 1, 2008

NCT ID
NCT00376337

About Micafungin + Systemic antifungal therapy

Micafungin + Systemic antifungal therapy is a phase 2 stage product being developed by Astellas Pharma for Invasive Aspergillosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00376337. Target conditions include Invasive Aspergillosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00376337Phase 2Terminated

Competing Products

20 competing products in Invasive Aspergillosis

See all competitors
ProductCompanyStageHype Score
BSG005Alkem LaboratoriesPhase 1/2
41
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
51
Trastuzumab deruxtecan + DurvalumabDaiichi SankyoPhase 2
52
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
77
Micafungin + fluconazoleAstellas PharmaPhase 3
77
MicafunginAstellas PharmaPre-clinical
23
Micafungin (Mycamine)Astellas PharmaPhase 1
33
Pudexacianinium chlorideAstellas PharmaPhase 2
52
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
52
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
52
Isavuconazonium sulfate + Voriconazole + PosaconazoleAstellas PharmaPre-clinical
23
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
77
Isavuconazonium sulfate + Isavuconazonium sulfateAstellas PharmaPhase 2
52
MicafunginAstellas PharmaPre-clinical
23
Micafungin + PlaceboAstellas PharmaPhase 3
77
MicafunginAstellas PharmaApproved
85
Olorofim + AmBisome®ShionogiPhase 3
77
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3
77
SHR-A1811 + Trastuzumab EmtansineJiangsu Hengrui MedicinePhase 3
77
Herombopag tablets + Herombopag placebo tabletsJiangsu Hengrui MedicinePhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85